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Increased expression and activity of inducible nitric
oxide synthase (iNOS) may contribute to the pathogen-
esis of pre-eclampsia (PE) and gestational hyperten-
sion (GH). However, no previous study has examined
whether genetic polymorphisms in the iNOS gene
are associated with PE or GH. We examined whether
two functional, clinically relevant iNOS genetic poly-
morphisms (the C1026A polymorphism, rs2779249, in
the promoter region, and the G2087A polymorphism,
rs2297518, in exon 16) are associated with GH or
with PE. We studied 565 pregnant women: 212 healthy
pregnant (HP), 166 pregnant with GH and 187 preg-
nant with PE. Genotypes were determined by real-time
PCR, using the Taqman allele discrimination assay.
The PHASE 2.1 program was used to estimate haplotype
distributions in the three study groups. We found no
significant association between the C1026A polymorph-
ism and PE or GH (P40.05). However, we found the GA
genotype and the A allele for the G2087A polymorphism
at higher frequency in PE, but not in GH, compared
with HP (Po0.05). The haplotype analysis showed no
significant intergroup differences (P40.05). These find-
ings suggest that iNOS genetic variants may affect the
susceptibility to PE, but not to GH.
Journal of Human Hypertension (2012) 26, 547–552;
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Introduction
Hypertensive disorders of pregnancy (HDP) are rela-
tively common complications of pregnancy which
increase maternal and fetal morbidity and mortality.
Two important HDP include pre-eclampsia (PE) and
gestational hypertension (GH). Although the etio-
logies of these conditions are not precisely known,
it is now becoming clear that several pathogenetic
mechanisms may be involved.1–5 For example, an
important mechanism possibly causing PE is abnor-
mal cytotrophoblast differentiation leading to hypo-
perfusion of placenta, hypoxia and release of some
soluble factors to the maternal circulation, thereby
causing systemic endothelial dysfunction.6–8 However,
other mechanisms involving altered formation of
nitric oxide (NO) have been implicated in HDP.4,9–13
In fact, there is now important evidence that impaired
endothelial-derived NO bioavailability contributes
to HDP.4,9–13
NO is synthesized from L-arginine by at least three
different nitric oxide synthases (NOS): neuronal,
endothelial and inducible NOS, respectively.14
Importantly, excessive amounts of NO may have
deleterious effects. Indeed, increased oxidative
stress has been reported in HDP, especially in PE,
with increased levels of the highly reactive species
superoxide reacting with NO to form peroxynitrite.15
This reaction may be favored by increased iNOS
expression because this enzyme produces huge
amounts of NO, thus possibly contributing to PE.16
However, while there is evidence that genetic
polymorphisms commonly found in the eNOS
gene may affect the susceptibility to HDP,10,11,13 no
previous study has examined whether genetic
polymorphisms in the iNOS gene are associated
with HDP in a relatively large number of patients,
even though there is a pilot study implicating iNOS
polymorphisms in PE.17 This is an important hypo-
thesis to be tested, especially because increased
vascular iNOS expression and activity has been
implicated in hypertension.18
In the present study, we examined whether
two functional, clinically relevant iNOS genetic
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polymorphisms (the C1026A polymorphism, rs2779249,
in the promoter region, and the G2087A polymor-
phism, rs2297518, in exon 16) are associated with GH
or with PE. These polymorphisms have been associated
with hypertension19,20 or with malignant neoplasias.21,22
Moreover, we have also studied whether iNOS haplo-
types combining the genetic variants for these poly-
morphisms are associated with HDP.
Materials and methods
Subjects
Approval for use of human subjects was obtained
from the Institutional Review Board at the Faculty of
Medicine of Ribeirao Preto, and informed consent
was obtained from each participant.
All volunteers were consecutively enrolled in the
Department of Obstetrics and Gynecology, University
Hospital of the Faculty of Medicine of Ribeirao Preto.
We studied 565 pregnant women: 212 healthy preg-
nant (HP), 166 pregnant with GH and 187 pregnant
with PE. HDP were defined in accordance with the
guidelines of the NHBPEP (National High Blood
Pressure Education Program Working Group on High
Blood Pressure in Pregnancy).23 GH was defined
as pregnancy-induced hypertension (X140 mm Hg
systolic or X90 mm Hg diastolic on X2 measure-
ments at least 6 h apart) in a woman after 20 weeks of
gestation, and returning to normal by 12 weeks post-
partum. PE was defined as increased blood pressure
plus significant proteinuria (X0.3 g per 24 h) in a
woman after 20 weeks of gestation. No women with
pre-existing hypertension, with or without super-
imposed PE, were included in the present study.
At the time of clinic attendance, maternal venous
blood samples were collected. Genomic DNA was
extracted from the cellular component of 1 ml of
whole blood and stored at 20 1C until analyzed.
Genotyping for iNOS polymorphisms
Two clinically relevant polymorphisms in the iNOS
gene were studied: the C1026A (rs2779249) and
the G2087A (rs2297518). Genotypes for these poly-
morphisms were determined by real-time PCR,
using the Taqman allele discrimination assay
(Applied Biosystems, Carlsbad, CA, USA). TaqMan
PCR was performed in a total volume of 12 ml (3 ng
of DNA, 1 TaqMan master mix, 1 assay mix,
900 nM of each primer and 200 nM of each probe)
placed in 96-well PCR plates. The probes and the
primers used in these genotypings were designed
by Applied Biosystems. Fluorescence from PCR
amplification was detected using Chromo 4 Detec-
tor (Bio-Rad Laboratories, Hercules, CA, USA) and
analyzed with manufacturer´s software.
Statistical analysis and study of iNOS haplotypes
The clinical characteristics of women with GH
or PE were compared with those of HP women by
Mann–Whitney U-test, w2 or Fisher exact, as appro-
priate. The distribution of genotypes for each
polymorphism was assessed for deviation from the
Hardy–Weinberg equilibrium, and differences in
genotype and allele frequencies among groups were
assessed using w2-tests or Fisher exact tests. A value
of Po0.05 was considered statistically significant.
The Bayesian statistical based program PHASE
(version 2.1, www.stat.washington.edu/stephens/
software.html) was used to estimate the haplotype’s
frequencies in each group.24,25 To further confirm
these frequencies we have also used the Haplo.stats
software (version 1.4.4, http://cran.r-project.org/
web/packages/haplo.stats/index.html), which com-
putes maximum likelihood estimates of haplotype
probabilities. The possible haplotypes including
genetic variants for the iNOS polymorphisms stu-
died (C or A variants for the C1026A polymorphism,
and G or A variants for the G2087A polymorphism)
were: H1 (CG), H2 (CA), H3 (AG) and H4 (AA).
Differences in haplotype frequency were further
tested using a contingency table. The minimum
level of statistical significance was corrected for the
number of comparisons made. Therefore, we con-
sidered significant a probability value of Po0.05/
number of haplotypes (Po0.05/4¼ 0.0125).
Results
Table 1 summarizes the characteristics of the 565
pregnant enrolled in the present study. We found no
differences in age, ethnicity, smoking, % primigra-
Table 1 Demographic characteristics of study subjects
Parameters Healthy
pregnant
(n¼212)
Gestational
hypertension
(n¼ 166)
Pre-
eclampsia
(n¼ 187)
Age (years) 26.5±6.6 26.5±6.8 26.9±6.0
Ethnicity (% white) 74.3 72.3 67.0
Current smoking (%) 14.6 20.7 16.3
Primigravida (%) 46.7 38.9 43.3
BMI (kg m2) 29.7±3.8 27.9±6.3 26.3±5.8
SBP (mm Hg) 112.7±10.6 131.4±16.5a 136.9±21.6a
DPB (mm Hg) 72.9±8.2 83.1±13.0a 86.7±12.41a
HR (beats per min) 82.8±6.8 82.2±7.9 81.7±7.6
Fasting glucose
(mmol l1)
4.04±0.63 4.08±0.47 4.14±0.65
Hb (g l1) 120±17 121±12 119±17
Hct (%) 35.6±5.2 36.3±3.5 36.2±5.2
Creatinine (mmol l1) 61.9±10.2 53.8±10.3 58.1±13.3
24-h-Pr (mg 24 h1) ND 153±76 1169±1665b
Newborn weight (g) 3258±575 3208±595 2777±816a
GAD (weeks) 39.7±3.3 38.6±4.0 35.6±2.8a
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure;
GAD, gestational age at delivery; HR, heart rate; Hb, hemoglobin
concentration; Hct, hematocrit; ND: not determined, however, with
negative dipstick test; SBP, systolic blood pressure; 24-h-Pr, 24-h
proteinuria.
Values are the mean ± s.d.
aPo0.05 vs healthy pregnant group.
bPo0.05 vs gestational hypertension group.
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vida, body mass index, heart rate, fasting glucose,
hemoglobin, hematocrit and creatinine levels when
HP, GH and PE women were compared (Table 1; all
P40.05). However, as expected, higher systolic and
diastolic blood pressures were found in the PE group
compared with the HP group (Table 1; both Po0.05).
Importantly, most hypertensive patients were receiving
pharmacological therapy (methyldopa in most cases).
Lower newborn weights and gestational ages at deli-
very were found in the PE group compared with the
HP group (Table 1; Po0.05). Significant proteinuria
was found in PE women.
The distribution of maternal genotypes for the two
polymorphisms studied here showed no deviation
from Hardy–Weinberg equilibrium (all P40.05). We
found no significant differences in genotype or in
allele distributions for the C1026A polymorphism
when the PE or the GH groups were compared with
the HP group (Table 2; all P40.05). However, the
genotype and allele frequencies for the G2087A
polymorphism were different in PE subjects as
compared with HP subjects. Indeed, the GA geno-
type and the A allele were more commonly found in
PE subjects compared with the HP group (Table 2;
both Po0.05). However, no significant differences
were found in genotypes and alleles distributions
when the GH group was compared with the HP
group (Table 2; all P40.05).
The haplotype analysis showed no significant
differences in overall distributions of haplotypes
frequencies when the GH or the PE group was
compared with the HP group (Table 3; all P40.05).
Discussion
The most important finding of the present study was
that the A allele for the G2087A polymorphism
increases the susceptibility to the development of
PE, but not GH. This is the first study to report a
significant association between maternal iNOS
genotypes and PE, and the first study to examine
whether iNOS polymorphisms are associated with
GH. Our findings are relevant because the search for
genetic markers associated with HDP may allow
early detection of increased susceptibility to disease
conditions associated with increased morbility and
mortality.10,26,27
Table 2 Genotype and allele frequencies for iNOS polymorphisms in healthy pregnant, gestational hypertension and pre-eclampsia
Polymorphism Genotype
or allele
Healthy pregnant
(n¼ 212)
Gestational
hypertension (n¼ 166)
OR (95% CI) P Pre-eclampsia
(n¼ 187)
OR (95% CI) P
C1026A
Genotypes CC 88 (41%) 67 (40%) 1.00 (reference) 67 (36%) 1.00 (reference)
CA 99 (47%) 78 (47%) 1.03 (0.67–1.60) NS 97 (52%) 1.29 (0.84–1.97) NS
AA 25 (12%) 21 (13%) 1.10 (0.57–2.13) NS 23 (12%) 1.21 (0.63–2.31) NS
w2¼ 0.09 NS w2¼ 1.39 NS
Alleles C 275 (65%) 212 (64%) 1.00 (reference) 231 (62%) 1.00 (reference)
A 149 (35%) 120 (36%) 1.05 (0.77–1.41) NS 143 (38%) 1.14 (0.86–1.53) NS
G2087A
Genotypes GG 155 (73%) 122 (73%) 1.00 (reference) 114 (61%) 1.00 (reference)
GA 53 (25%) 44 (27%) 1.05 (0.66–1.68) NS 68 (36%)a 1.74 (1.13–2.69) 0.01
AA 4 (2%) 0 0.10 (0.01–1.75) NS 5 (3%) 1.13 (0.34–3.80) NS
w2¼ 4.78 NS w2¼ 6.41 0.04
Alleles G 363 (86%) 288 (87%) 1.00 (reference) 296 (79%) 1.00 (reference)
A 65 (14%) 44 (13%) 0.85 (0.57–1.29) NS 78 (21%)a 1.47 (1.02–2.12) 0.04
Abbreviations: CI, confidence interval; NS, not significant; OR, odds ratio.
aPo0.05 vs healthy pregnant group.
Table 3 Estimated haplotype frequencies in healthy pregnant, gestational hypertension and pre-eclampsia
Haplotype Healthy
pregnant
(n¼212)
Gestational
hypertension
(n¼ 166)
OR (95% CI) P Pre-eclampsia
(n¼ 187)
OR (95% CI) P
C1026A G2087A
H1 C G 0.59 0.59 1.00 NS 0.53 1.00 NS
H2 C A 0.06 0.05 0.88 (0.41–1.89) NS 0.08 1.42 (0.72–2.81) NS
H3 A G 0.26 0.28 1.09 (0.77–1.56) NS 0.30 1.24 (0.88–1.76) NS
H4 A A 0.09 0.08 0.86 (0.50–1.50) NS 0.09 1.04 (0.61–1.80) NS
w2¼1.05 w2¼3.80
Abbreviations: CI, confidence interval; NS, not significant; OR, odds ratio.
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Our findings implicating the G2087A polymor-
phism in the susceptibility to PE align with previous
studies showing that this polymorphism affects
the susceptibility to other disease conditions in-
cluding diabetes, prostate cancer and non-Hodgkin
lymphoma.21,22,28 Interestingly, although iNOS is
mainly regulated at the transcriptional level,14 this
polymorphism in exon 16 results in an amino acid
substitution from serine to leucine, which increases
iNOS activity and promotes excessive NO formation
and inflammation.21 Therefore, the significant asso-
ciation that we found between the A allele for the
G2087A polymorphism and PE can be explained by
increased tissue iNOS activity in subjects carrying
this allele. This suggestion is supported by experi-
mental evidence indicating that increased iNOS
activity contributes to the pathogenesis of hyper-
tension in spontaneously hypertensive rats.18 The
use of an iNOS inhibitor (aminoguanidine) pre-
vented the development of hypertension and this
finding was associated with lowered nitro-tyrosine
levels, which may reflect blunted NO and lower
peroxinitrite formation with this iNOS inhibitor.18
Further supporting our suggestion, endothelial cells
exposed to plasma from pre-eclamptic pregnant
increased NOS activity,29 and therefore it is highly
probable that increased NO formation in a context of
increased oxidative stress promotes the formation
of peroxinitrite and an inflammatory state with
vascular damage.16 Indeed, a cascade of inflamma-
tory mechanisms may be activated as a result of
increased iNOS activity leading to increased vascu-
lar peroxinitrite levels. For example, matrix metal-
loproteinases may be activated by peroxynitrite,30
and these enzymes may have a role in the patho-
genesis of PE.16 These possible alterations may be
more relevant in PE patients carrying the A allele for
the G2087A polymorphism than in GH patients,
because the iNOS polymorphisms studied here were
not associated with GH. It remains to be determined
whether these alterations are associated with dis-
ease severity or whether they may help to explain
why PE patients are at increased risk of developing
cardiovascular diseases.31
The promoter region of the iNOS gene is complex.
Because iNOS transcription is the most important
level of iNOS regulation,14 genetic polymorphisms
that modify the promoter region of this gene are
expected to significantly affect iNOS expression and
therefore modulate disease susceptibility. In fact,
the iNOS promoter region has been widely studied
and genetic polymorphisms in this region have been
associated with several diseases including hyper-
tension.32 However, the lack of significant associa-
tion between the C1026A polymorphism and PE or
GH reported here suggests that this iNOS poly-
morphism may have no impact on iNOS biology
in HDP. To our knowledge, no previous study
has examined whether the C1026A polymorphism
is associated with HDP. Our negative findings
with respect to this polymorphism are unexpected
because this polymorphism was associated with
susceptibility to hypertension,20,32 and the A allele
for this polymorphism was associated with approxi-
mately fivefold increases in iNOS promoter tran-
scriptional activity compared with the C allele.20
Our results may suggest that HDP may not critically
involve alterations of transcriptional activity asso-
ciated with this polymorphism in the promoter
region of iNOS gene, even though this may well be
the case of clinical hypertension.20 However, we
have not examined molecular mechanisms in the
present study, and this hypothesis remains to be
proved.
We found no significant associations between
iNOS haplotypes and PE or GH. Although haplo-
type analysis is valued as a more powerful and
interesting approach than the analysis of single
polymorphisms, it may be less informative when
a causal connection between genetic variations
and a phenotype is really driven by a single
polymorphism.33,34 This may well be the case of
the present study, because we found significant
association between the G2087A polymorphism
and PE.
Our study focused on the effects of maternal iNOS
genotypes on the susceptibility to PE or GH. It
should be clear that fetal genotypes for iNOS
polymorphisms may have more important contri-
bution to the risk of developing these diseases.
However, this hypothesis remains to be tested.
In conclusion, our results indicate that the
G2087A polymorphism affects the susceptibility to
PE, but not to GH. Whereas we found lack of
significant associations between iNOS polymorph-
isms and GH, possibly suggesting that different
pathophysiological mechanisms are involved in
these hypertensive disorders, further studies are
required.
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What is known about this topic
K Experimental studies showed that increased iNOS
(inducible nitric oxide synthase) activity has a role in the
pathophysiology of hypertension.
K Although genetic polymorphisms in the iNOS gene have
been associated with hypertension, no previous study
has examined whether functional iNOS polymorphisms
affect the susceptibility to gestational hypertension or to
pre-eclampsia.
What this study adds
K Whereas the genotype for the G2087A (rs2297518)
polymorphism in the iNOS gene affects the susceptibility
to pre-eclampsia, the C1026A (rs2779249) polymorphism
does not.
K Both iNOS polymorphisms are not associated with
gestational hypertension.
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